We also determined whether reducing PPFIA1 mRNA levels by treatment with either PPFIA1 siRNA or miR-181a mimic could attenuate the CML malignant behavior. The gene discussed is PPFIA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.